Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10629902 | 0.82 | ACHE (0.68) | ACHEEPHX2 | |
| SCHEMBL23077374 | 0.80 | ACHE (0.50) | ACHEHTTEPHX2 | |
| SCHEMBL10742242 | 0.80 | ACHE (0.60) | ACHEEPHX2 | |
| SCHEMBL23436332 | 0.79 | EPHX1 (0.63) | ACHEEPHX2 | |
| SCHEMBL23666220 | 0.79 | EPHX1 (0.63) | ACHEEPHX2 | |
| SCHEMBL16239977 | 0.77 | ACHE (0.55) | ACHE | |
| SCHEMBL14090769 | 0.76 | ACHE (0.42) | ACHEHTTEPHX2 | |
| SCHEMBL9602960 | 0.73 | — | — | |
| SCHEMBL23077522 | 0.72 | ACHE (0.47) | ACHEHTTEPHX2 | |
| SCHEMBL4970523 | 0.72 | ACHE (0.72) | ACHEEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3802534-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORP (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220073509-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2022-03-10 | — | — | US | disclosed |
| EP-3802534-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | Incyte Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073509-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | STING1, MAVS, IRF3 | ACHE 3434/4885HTT 3928/4885EPHX2 3406/4885 |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | STING1, MAVS, IRF3 | ACHE 3434/4885HTT 3928/4885EPHX2 3406/4885 |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | STING1, MAVS, IRF3 | ACHE 3434/4885HTT 3928/4885EPHX2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.